“Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus”, J of Skin, vol. 7, no. 4, p. s226, Jul. 2023, doi: 10.25251/skin.7.supp.226.